Gladson study finds that product dimensions are off for product displays
LISLE, Ill. A study conducted by Gladson Interactive, a provider of product images for the consumer goods industry, reveals that 90 percent of the over 200,000 products examined contained at least one error in either product height, width or depth dimensions. Significantly, nearly one in every five products had errors of greater than 25 percent.
These dimensional errors in the Product Information Masterfile are a leading factor in store out-of-stocks, a major cause of consumer dissatisfaction, the company reported. “Studies conducted in the mid-1990’s by a leading packaged goods manufacturer estimated that a planogram goes out of compliance at the rate of 10 percent each week,” stated Mike Spindler, Gladson chief executive officer. “Based on our findings, there is a high probability that most planograms are never set as intended in the first place due to these product measurement inaccuracies.”
Moreover, inaccuracies at the product item-level were found to be as costly to demand chain applications as case-level inaccuracies were to supply chain applications and a significant hindrance to the long-time industry goal of data synchronization.
While all three dimensions are important, package width most directly affected consumer presentation, the Gladson study found—76 percent of the products in retailer planograms were measured as either narrower or wider than they actually were supposed to be. In total, these width errors represent over a foot per shelf for the average section.
CRN to sponsor research on healthcare professionals’ use of dietary supplements
WASHINGTON ”Life…supplemented,” an advertising campaign managed by the Council for Responsible Nutrition, on Thursday announced that it is sponsoring new research among healthcare professionals to better understand their personal use of dietary supplements and how it may impact the way they counsel their patients about dietary supplements.
“A search of the current medical literature reveals less than a dozen articles in peer-reviewed publications on the subject of personal use of supplements among clinicians, with papers published since 2000 clearly reflecting a growing interest in the topic among academicians,” stated Steve Mister, CRN’s president and chief executive officer
Mister noted, however, that because of the disparities among definitions of dietary supplements, instruments and populations surveyed, more questions are raised than are answered. “At this stage, it’s impossible to say with certainty whether the personal use of supplements by healthcare professionals correlates to their recommendations to patients.”
“This represents a significant knowledge gap that needs to be addressed,” stated Tieraona Low Dog, director of education for the University of Arizona’s Program in Integrative Medicine. “At this time, we do not know how the majority of healthcare professionals view dietary supplements in terms of their own health, or how these views then impact their discussions with patients in the clinical setting.”
Results of the survey, which will be fielded during September, are expected to be released in early November.
The online survey has been developed with Ipsos, a leading research firm.
B&L shareholders vote for merger
ROCHESTER, N.Y. Bausch & Lomb on Friday announced that its shareholders voted to approve the proposed merger with affiliates of Warburg Pincus at a special meeting of shareholders held earlier this morning.
“We are pleased with the outcome of today’s vote,” stated Ronald Zarrella, chairman and chief executive officer of Bausch & Lomb. “On behalf of the Bausch & Lomb Board and management team, I want to thank our shareholders, customers and dedicated employees for their support throughout this process. We look forward to promptly completing the transaction.”
The tabulation indicates that more than two thirds of the total shares outstanding and entitled to vote at the meeting were voted in favor of the transaction.
In accordance with the terms of the merger agreement, at the closing, each outstanding share of common and Class B stock of Bausch & Lomb will be cancelled and converted into the right to receive $65 in cash, without interest, less any applicable withholding taxes. The transaction, which is subject to customary closing conditions, is expected to close early in the third quarter. Pursuant to the merger agreement, affiliates of Warburg Pincus are not required to consummate the merger until after expiration of a “marketing period” of 20 business days following the shareholder vote. Closing of the merger is not subject to a financing condition.